Background: The PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine
Impact on Global Mortality and morbidity in Heart Failure) trial was a double-blind trial that …

Abstract Aims The PARADIGM‐HF trial showed that sacubitril–valsartan, an ARB–neprilysin
inhibitor, is more effective than enalapril for some patients with heart failure (HF). It is …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

The Prospective comparison of Angiotensin Receptor-neprilysin inhibitor (ARNI) with
Angiotensin converting enzyme inhibitor (ACEI) to Determine Impact on Global Mortality and …

Our aim was to summarize published secondary analyses of the PARADIGM‐HF trial. In the
original trial, published in September 2014, sacubitril/valsartan significantly reduced the …

Background Sacubitril/valsartan, the first agent to be approved in a new class of drugs called
angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular …

Background Heart failure (HF) with reduced ejection fraction represents approximately 50%
of the 600,000 Canadians currently living with HF and over 90,000 new cases diagnosed …

Current guidelines recommend angiotensin receptor blocker neprilysin inhibitors
(ARNI)(sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor …

Aims This study aims to investigate the eligibility of the Prospective Comparison of
Angiotensin Receptor–Neprilysin Inhibitor (ARNI) with ACE inhibitor to Determine Impact on …

Aims Practice guidelines recommend sacubitril/valsartan for heart failure with reduced
ejection fraction. The aim of our study was to describe the use of sacubitril/valsartan in real …